No evidence of active graft versus host disease (GVHD) and >= 2 months must have elapsed since transplant or rescue
Patients with graft versus-host disease (GVHD)
Patients with evidence of graft versus host disease (GVHD) > grade II at time of enrollment
Patients must have fully recovered from the acute effects of all prior therapy and cannot have evidence of graft-versus-host disease (GVHD)
Evidence of graft versus host disease (GVHD) > grade II
Evidence of graft versus host disease (GVHD) > grade II
Evidence of graft versus host disease (GVHD) > grade II
Grade III/IV acute graft-versus-host disease (GVHD)
Presence of graft-versus-host disease (GVHD) more than grade 2
Presence of acute or chronic graft-versus-host disease (GVHD) unless limited to skin involvement and managed with topical steroid therapy alone
Active acute graft versus host disease (GVHD) grade >= 2.
Presence of acute or chronic graft-versus-host disease (GVHD) unless limited to skin involvement and managed with topical steroid therapy alone
Active acute graft versus (vs.) host disease >= grade 2 or active extensive chronic graft versus host disease (GVHD)
Presence of active acute or chronic graft versus host disease (GVHD)
Graft versus host disease (GVHD) grade III or IV
CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: Presence of active acute or chronic graft versus host disease (GVHD)
Patients with prior history of or active severe (grade 3 or 4) acute graft-versus-host disease (GVHD)
Subjects must not have a history of severe (grade 3-4) acute graft versus host disease (GVHD), and/or current > grade 1 acute GHVD; subjects must not have a history of active chronic GVHD (whether limited or extensive stage)
Active graft versus (vs.) host disease (gvhd)
No uncontrolled graft versus host disease (GVHD)
Active acute graft versus host disease (GVHD) grade II or higher
Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy
Patients with active acute graft-versus-host disease (GVHD) grades II-IV
Patients with active acute graft versus host disease (GVHD) grades II-IV.
Patients with active acute graft-versus-host disease (GVHD) grades II-IV
Patients with active acute graft-versus-host disease (GVHD) grades II-IV
Active acute or chronic graft-versus-host disease (GVHD)
Patients with untreated or uncontrolled grade 3 or 4 graft-versus-host disease (GVHD)
Has active graft-versus-host disease (GVHD).
Active graft-versus-host disease (GvHD) grades II-IV; prior acute GVHD could have occurred but resolved at time of initiation of daratumumab
Acute graft versus host disease (GVHD) or active chronic GVHD greater than grade 1
Active acute graft-versus-host disease (GvHD) or chronic GVHD grade 2 or higher
Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD)
Presence of grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD).
Patient has evidence of graft versus host disease (GVHD)
Patient has evidence of active graft versus host disease (GVHD)
Anti Graft-Versus-Host Disease (GVHD) therapy within 12 weeks before the first dose of study drug
Presence of acute or extensive chronic graft versus host disease (GVHD)
Acute graft-versus-host disease (GvHD), classic (=< day 100) or late-onset (> day 100)
Patients on investigational therapy for graft-versus-host disease (GVHD)
Currently taking corticosteroids for therapy of graft-versus-host disease (GVHD)
Presence of steroid-refractory acute graft-versus-host disease (GVHD)
Less than 100 days post -transplant or any evidence of active graft-versus-host disease (GVHD)
Acute graft-versus-host disease (GVHD) at time of enrollment (history of treated and resolved GVHD is permitted)
Patients with active acute Graft versus host disease (GVHD) grades II-IV.
Active acute graft-vs-host disease (GVHD) grades II-IV
Active acute graft vs. host disease >= grade 2 or active extensive chronic graft-versus-host disease (GVHD)
Patient has evidence of graft versus host disease (GVHD).
Refractory graft versus host disease (GvHD) not responding to treatment
Acute graft versus host disease (GVHD) fitting one of the following categories:
Any graft-versus-host disease (GVHD) prophylaxis regimen is allowed
Prior bone marrow transplant within 3 months or with acute graft versus host disease (GVHD)
Patients actively enrolled on any other graft versus host disease (GVHD) prevention trial
Patients with active acute graft-versus-host disease (GVHD) grades II-IV
No signs or symptoms of acute graft versus host disease; however prior acute GVHD which is resolved and controlled with low dose steroids (< 0.3 mg/kg/day for at least 1 week) may be eligible
Patients with graft-versus-host disease (GVHD) > grade II
Presence of acute or chronic graft-versus-host disease (GVHD)
Acute graft versus host disease (GvHD) Grade III or IV, or severe chronic GvHD.
